Robert James

Managing Partner

Robert has worked in the commercial exploitation of intellectual property for more than 20 years. He first worked at Cancer Research Campaign Technology (now Cancer Research Technology, the commercialisation and development arm of Cancer Research UK) for seven years before moving to the early stage venture capital company, Prelude Ventures. He was a founding Partner of DFJ Esprit before leaving in 2010 to create Sixth Element Capital. Robert has been involved in many early stage technologies and businesses which in aggregate have raised over £200m in financing and has been involved in raising four VC funds. He played a central role in licensing Temodal to Schering Plough and the PARP inhibitor Rucaparib to Agouron (now Clovis); he has been lead investor in successful life science technologies and businesses in diagnosis, tools and therapeutics such as Oxford Immunotec (Nasdaq:OXFD), Kiadis (Euronext:KDS) and DNA Research Innovations (now owned by ThermoFisher Scientific). Robert has a PhD in Biochemistry and a degree in Genetics.